Reuters logo
4 个月前
BRIEF-Genentech says FDA grants breakthrough therapy designation for Rituximab in Pemphigus Vulgaris
2017年3月24日 / 凌晨5点05分 / 4 个月前

BRIEF-Genentech says FDA grants breakthrough therapy designation for Rituximab in Pemphigus Vulgaris

1 分钟阅读

March 24 (Reuters) - Genentech:

* FDA grants breakthrough therapy designation for Rituxan (rituximab) in Pemphigus Vulgaris

* U.S. Food and drug administration (fda) has granted breakthrough therapy designation status to Rituxan Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below